CDKN1B and neoplasm: Octreotide and pasireotide treatment increased CDKN1A/B (cell cycle-brakes [74]) mRNA levels, which is consistent with reports in other tumour types reporting antiproliferative effects through the reduction of their respective proteins (p21 and p27) [75–78].